(CercleFinance.com) – The biopharmaceutical company Lysogene, which has been in financial difficulty for several months, has announced that it has been placed in compulsory liquidation proceedings by the Commercial Court of Nanterre.
The company, which was already the subject of receivership, informs that the listing of its shares, which had been suspended since the beginning of January, will not resume and that a request for delisting will be made soon to Euronext.
Following the failure of its Phase II/III study on its gene therapy in MPS IIIA, a rare recessive neurodegenerative disease, the company found itself short of cash and no buyer had come forward.
Introduced at a unit price of 6.80 euros per share in 2017, the share less than 0.3 euro during the last exchanges.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
